

Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: December 6th, 2023
Time and Location: 1:00 pm CST in Bismarck, North Dakota

Call to Order:

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:06 pm CST. Motion moved by A. Werremeyer to have pro tem Presiding Officer K. Martian presiding and seconded by T. Schmidt. **Motion carried.** DUR Board Coordinator, C. Stauter recording minutes.

Roll Call:

Board Members Voting:

Present: Stephanie Antony, Josh Askvig, Gabriela Balf, Kurt Datz, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Kristen Peterson, Tanya Schmidt, Amy Werremeyer

Absent: Jennifer Iverson

Quorum Present: Yes

Board Members Non-Voting:

Absent: Kathleen Traylor

Medicaid Pharmacy Department:

Present: Brendan Joyce, Alexi Murphy, LeNeika Roehrich

Absent: Jeff Hostetter

Approval of Meeting Minutes:

Motion: Moved by L. Kroetsch to approve the minutes of the September 6th, 2023 meeting, motion was seconded by K. Peterson. **Motion carried.**

The minutes of the September 6th, 2023, meeting were approved as distributed.

Reports:

Administrative Report: Rebates by A. Murphy

A. Murphy shared with the Board changes to rebate calculations. This information can be found in the handout.

Financial Report: Budget provided by B. Joyce

B. Joyce shared with the Board trends of pharmacy claims costing over \$5000 from August 2023. This information can be found in the handout.

Financial Report: Top Drugs provided by B. Joyce

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Report by C. Stauter

C. Stauter reviewed the quarterly RDUR criteria that were selected for review of each month, including a special mailing letter from July 2023. This material can be found in the handout.

Clinical Report: Annual PDL Review and Criteria Updates by C. Stauter

C. Stauter discussed updates to the Preferred Drug List (PDL) throughout the year 2023, with emphasis on the following sections in the PDL: cholestasis pruritis, diabetes, and Hepatitis C.

The presented information can be found in the handout. Testimony was provided by the following: Phong Pham from Ipsen Biopharmaceuticals on Bylvay; Shawn Hansen from Novo Nordisk on Ozempic and Rybelsus; Erin Nowak from Abbvie on Mavyret, Rinvoq, Skyrizi, and Ubrelvy; Phil Wettstad from Novartis on Leqvio and Cosentyx; Christine Dubé from AstraZeneca on Brilinta, Lokelma, and Fasenra; John Deason from Neurocrine Biosciences on Ingrezza.

New business:

Second Reviews provided by C. Stauter

C. Stauter presented group prior authorization criteria for diuretics and menopause. The presented material can be found in the handout.

Motion: Moved by K. Peterson to place diuretics on prior authorization, motion was seconded by K. Martian. **Motion carried.**

Motion: Moved by T. Schmidt to place agents for menopause on prior authorization, motion was seconded by A. Werremeyer. **Motion carried.**

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Martian to approve the RDUR criteria, motion was seconded by T. Schmidt. **Motion carried.**

Announcements:

Next meeting is March 6th, 2024.

Adjournment:

Meeting adjourned by K. Martian at 2:32 pm CST.

Date of Minutes Approval: March 6, 2024

Minutes submitted by: Claire Stauter, Acentra Health